Can-Fite (CANF) Shares Rise On Favorable Psoriasis Data

Can-Fite BioPharma Ltd. (CANF) shares are up 55% to $3.36 in mid-day trading after the company’s announcement of positive results from further analysis of its phase II/III Psoriasis trial. The biotechnology firm said the entire study period revealed that by 32 weeks of treatment with CF101, 33% of the patients achieved PASI 75 while the […] View the full post at: Can-Fite (CANF) Shares Rise On Favorable Psoriasis Data Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Economic Data: CPI Higher than Expected Morgan Stanley exec: Rapid rise in hedge fund launches
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.